Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15906692 | 0.86 | TSHR (0.50) | TSHRSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL7500859 | 0.86 | TSHR (0.50) | TSHRSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL544031 | 0.85 | KMT2A (0.53) | TSHRSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL305239 | 0.84 | TSHR (0.63) | TSHRMEN1KMT2AALDH1A1POLB | |
| SCHEMBL14249239 | 0.84 | SMN1; SMN2 (0.49) | TSHRSMN1; SMN2MEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL7418132 | 0.83 | TSHR (0.61) | TSHRMEN1KMT2AALDH1A1POLB | |
| SCHEMBL430054 | 0.83 | SLC6A2 (0.58) | TSHRSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL28003093 | 0.83 | TSHR (0.49) | TSHRSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL307312 | 0.82 | TSHR (0.70) | TSHRSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL29959661 | 0.82 | TSHR (0.70) | TSHRSMN1; SMN2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2994469-B1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES INC (US) | 2018-12-19 | — | — | EP | disclosed |
| US-20180282316-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2018-10-04 | — | — | US | disclosed |
| US-10017501-B2 | Benzimidazole derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017501-B2 | Benzimidazole derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| EP-2978759-B1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES INC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20160376261-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2016-12-29 | — | — | US | disclosed |
| US-20160376261-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2016-12-29 | — | — | US | disclosed |
| US-9458145-B2 | Benzimidazole derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458145-B2 | Benzimidazole derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458145-B2 | Benzimidazole derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| EP-2125753-A1 | FUSED HETEROCYCLIC COMPOUNDS HAVING CRF ANTAGONISTIC ACTIVITY | Takeda Pharmaceutical Company Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
| EP-2088861-A2 | BENZIMIDAZOLE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2009-08-19 | — | — | EP | disclosed |
| EP-1874736-A4 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2008-08-20 | — | — | EP | disclosed |
| WO-2008082003-A1 | FUSED HETEROCYCLIC COMPOUNDS HAVING CRF ANTAGONISTIC ACTIVITY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008051533-A2 | BENZIMIDAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-02 | — | — | WO | disclosed |
| CN-101166729-A | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL (JP) | 2008-04-23 | — | — | CN | disclosed |
| EP-1874736-A2 | FUSED HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006116412-A2 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-02 | — | — | WO | disclosed |
| US-6855713-B2 | Benzimidazole derivatives, a process for their manufacture and use as a medicine | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-02-15 | — | — | US | disclosed |
| US-20030130265-A1 | Benzimidazole derivatives, a process for their manufacture and use as a medicine | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282316-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | TSHR 2264/4885SMN1; SMN2 3348/4885MEN1 2554/4885 |
| US-20030130265-A1 | Benzimidazole derivatives, a process for their manufacture and use as a medicine | TPSAB1, PRSS3, TPSD1 | TSHR 969/4885SMN1; SMN2 2833/4885MEN1 2446/4885 |
| US-10017501-B2 | Benzimidazole derivatives as bromodomain inhibitors | BRD4, BRD3, BRD1 | TSHR 2264/4885SMN1; SMN2 3348/4885MEN1 2554/4885 |
| US-20160376261-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | TSHR 2264/4885SMN1; SMN2 3348/4885MEN1 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.